AI Article Synopsis

  • Adult growth hormone deficiency (AGHD) is often underdiagnosed, leading to various health issues and decreased quality of life for those affected; symptoms in adults are less obvious and lack straightforward testing methods.
  • A panel of 9 AGHD patients shared experiences highlighting difficulties in diagnosis, including numerous specialist visits, repeated tests, and frustrations with insurance resistance on treatment approvals.
  • The findings stress the urgent need for improved screening and identification of AGHD, better clinician and insurance company understanding of the need for ongoing GH therapy, and enhanced patient support for treatment access.

Article Abstract

Adult growth hormone deficiency (AGHD) is a rare and serious condition associated with significant morbidity, including reduced quality of life, and is underdiagnosed and often missed in patients. Although the onset of AGHD can occur in either childhood or adulthood, adult-onset AGHD is more difficult to identify as it lacks the auxologic signs caused by GHD during childhood, includes symptoms that tend to be nonspecific, and lacks reliable, simple biomarker testing options. A panel of 9 patients with AGHD (3 with childhood onset; 6 with adult onset) was assembled to share their first-hand experiences, to help reveal important areas of need, increase health literacy, and to raise awareness about GHD among patients, caregivers, and healthcare practitioners. Interviews with patients yielded valuable insights from the patient perspective to supplement prior knowledge about AGHD symptomatology, biomarker testing, and treatment outcomes. Some patients described a burdensome and ineffective screening process that sometimes included many visits to different specialists, repeated rounds of biomarker testing, and, in some cases, excessive delays in AGHD diagnosis. All patients expressed frustration with insurance companies that often resist and/or delay treatment authorization and reimbursement and frequently require additional testing to verify the diagnosis, often leading to treatment gaps. These findings emphasize the necessity of more efficient identification and screening of patients with possible AGHD, better recognition by clinicians and insurance providers of the importance of sustained GH replacement therapy during adulthood, and better patient support for accessing and maintaining uninterrupted GH replacement therapy for patients with documented AGHD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165431PMC
http://dx.doi.org/10.1210/jendso/bvac077DOI Listing

Publication Analysis

Top Keywords

biomarker testing
12
adult growth
8
growth hormone
8
hormone deficiency
8
aghd
8
patients
8
patients aghd
8
replacement therapy
8
deficiency diagnostic
4
treatment
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!